Press release
Idiopathic Pulmonary Fibrosis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Biogen, Bristol-Myers Squibb, Celgene, Roche, Galapagos NV, Boehringer Ingelheim, ProMetic Life Sciences, Taiho Pharma
"Idiopathic Pulmonary Fibrosis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Idiopathic Pulmonary Fibrosis Therapeutics Market.
The report provides a detailed description of the Idiopathic Pulmonary Fibrosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Idiopathic Pulmonary Fibrosis Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Idiopathic Pulmonary Fibrosis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Idiopathic Pulmonary Fibrosis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Idiopathic Pulmonary Fibrosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Idiopathic Pulmonary Fibrosis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Idiopathic Pulmonary Fibrosis Therapeutics Domain:
https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Idiopathic Pulmonary Fibrosis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Request for Sample PDF to Understand More About the Idiopathic Pulmonary Fibrosis Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Latest Key Update in the Idiopathic Pulmonary Fibrosis Therapeutics Market
On April 03, 2023, FibroGen, Inc. (NASDAQ: FGEN) announced the completion of patient enrollment for ZEPHYRUS-2, a Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease.
Idiopathic Pulmonary Fibrosis Therapeutics Analysis
There are approx. 80+ key companies developing therapies for Idiopathic Pulmonary Fibrosis. Currently, Hoffmann-La Roche is leading the therapeutics market with its Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage of clinical development.
Idiopathic Pulmonary Fibrosis Companies in the Therapeutics Market Include:
Algernon Pharmaceuticals, Astra Zeneca, Avalyn Pharmaceuticals, Bellerophon Therapeutics, Boehringer Ingelheim, Bridge Biotherapeutics, Bristol-Myers Squibb, Calliditas Therapeutics, Celgene Pharmaceutical, CSL Behring, Daewoong Pharmaceutical, Endeavor BioMedicines, FibroGen, Galecto Biotech AB, Guangdong Raynovent, Horizon Therapeutics, Insmed, Kadmon Pharmaceuticals, Kinarus AG, Lung Therapeutics, MediciNova, Metagone Biotech, Nitto Denko, Novartis, Pliant Therapeutics, PureTech Health, Regend Therapeutics, Roche, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Syndax Pharmaceuticals, Taiho Pharmaceutical, United Therapeutics, Vicore Pharma, and others.
Emerging and Marketed Idiopathic Pulmonary Fibrosis Therapies Covered in the Report Include:
• BG-00011: Biogen
• BMS-986020: Bristol-Myers Squibb
• CC-90001: Celgene Corporation
• ESBRIET (Pirfenidone): Hoffmann-La Roche Ltd
• Gefapixant: Merck & Co., Inc.
• GLPG4716: Galapagos NV
• LT-1002: Chong Kun Dang Pharmaceutical
• OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
• Pamrevlumab: FibroGen, Inc.
• PBI4050: ProMetic Life Sciences
• PLN-74809: Pliant Therapeutics
• PRM-151 (RG6354): Hoffmann-La Roche Ltd
• TAS-115: Taiho Pharmaceutical
• TD139 (Bristol-Myers Squibb
• Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
• Tipelukast: MediciNova
• Tyvaso (inhaled treprostinil): United Therapeutics
• VAY-736: MorphoSys; Novartis
And Many Others
Get an in-depth Assessment of the Emerging Therapies and Idiopathic Pulmonary Fibrosis Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Idiopathic Pulmonary Fibrosis Current Treatment Patterns
4. Idiopathic Pulmonary Fibrosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Idiopathic Pulmonary Fibrosis Late-Stage Products (Phase-III)
7. Idiopathic Pulmonary Fibrosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Idiopathic Pulmonary Fibrosis Discontinued Products
13. Idiopathic Pulmonary Fibrosis Product Profiles
14. Idiopathic Pulmonary Fibrosis Companies
15. Idiopathic Pulmonary Fibrosis Drugs
16. Dormant and Discontinued Products
17. Idiopathic Pulmonary Fibrosis Unmet Needs
18. Idiopathic Pulmonary Fibrosis Future Perspectives
19. Idiopathic Pulmonary Fibrosis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Mucinous Cystic Neoplasms (MCNs) Market
https://www.delveinsight.com/report-store/mucinous-cystic-neoplasms-mcns-market
Overt Hepatic Encephalopathy Market
https://www.delveinsight.com/report-store/overt-hepatic-encephalopathy-market
Familial Hypercholesterolemia Market
https://www.delveinsight.com/report-store/familial-hypercholesterolemia-market-report
Lateral Epicondylitis (Tennis Elbow) Disease Market
https://www.delveinsight.com/report-store/lateral-epicondylitis-tennis-elbow-disease-market
Diverticulitis Market
https://www.delveinsight.com/report-store/diverticulitis-market
Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market
Charcot-Marie-Tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
Neurovascular Thrombectomy Devices Market
https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Neurothrombectomy Devices Market
https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Stargardt Disease (STGD) Market
https://www.delveinsight.com/report-store/stargardt-disease-stgd-market
Venous Leg Ulcer Market
https://www.delveinsight.com/report-store/venous-leg-ulcer-market
Genital Herpes Market
https://www.delveinsight.com/report-store/genital-herpes-market-forecast
Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market
Morquio Syndrome Market
https://www.delveinsight.com/report-store/morquio-syndrome-market
Lymphoedema Market
https://www.delveinsight.com/report-store/lymphoedema-market
Neurotrophic Keratopathy Market
https://www.delveinsight.com/report-store/neurotrophic-keratopathy-market
Oncolytic Virus Cancer Therapy Market
https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market
Orthostatic Hypotension Market
https://www.delveinsight.com/report-store/orthostatic-hypotension-market
Advanced Wound Care (AWC) Market
https://www.delveinsight.com/report-store/advanced-wound-care-market
Opioid-related Disorders Market
https://www.delveinsight.com/report-store/opioid-related-disorders-market
Ankylosing Spondylitis (AS) Market
https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market
Chronic Insomnia Market
https://www.delveinsight.com/report-store/chronic-insomnia-market
Microscopic Polyangiitis (MPA) Market
https://www.delveinsight.com/report-store/microscopic-polyangiitis-mpa-market
Esophageal Squamous Carcinoma Market
https://www.delveinsight.com/report-store/esophageal-squamous-carcinoma-market
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market
Chemotherapy Induced Neutropenia (CIN) Market
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
Idiopathic Interstitial Pneumonia Market
https://www.delveinsight.com/report-store/idiopathic-interstitial-pneumonia-market
Diphtheria Market
https://www.delveinsight.com/report-store/diphtheria-market
Dyslipidemia Market
https://www.delveinsight.com/report-store/dyslipidemia-market
Thymus Cancer Market
https://www.delveinsight.com/report-store/thymus-cancer-market
Tendonitis Market
https://www.delveinsight.com/report-store/tendonitis-market
Alpha-Antitrypsin Deficiency Market
https://www.delveinsight.com/report-store/alpha-antitrypsin-deficiency-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Pulmonary Fibrosis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Biogen, Bristol-Myers Squibb, Celgene, Roche, Galapagos NV, Boehringer Ingelheim, ProMetic Life Sciences, Taiho Pharma here
News-ID: 3161852 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Idiopathic
Idiopathic Pulmonary Fibrosis Market Size & Share Analysis
The new report published by The Business Research Company, titled Idiopathic Pulmonary Fibrosis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $3.89…
Idiopathic Pulmonary Fibrosis Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Idiopathic Pulmonary Fibrosis Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth …
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria).
R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In…
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, …
Global Idiopathic Scoliosis Treatment Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatment Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments.
Get Sample…
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation…
